Published on : Aug 26, 2017
Albany, New York, August 26, 2017: Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver, responsible for significant morbidity and mortality worldwide. Inventions in technologies for cancer treatment procedures are expected to launch into the market in the coming years. Moreover, the increasing investment of pharmaceutical companies in the research and development of anti-cancer drugs would contribute to the growth of hepatocellular carcinoma treatment market. A new pipeline study, related to the therapeutics activities for Metastatic Hepatocellular Carcinoma has been recently broadcasted to the wide repository of Market Research Hub (MRH), with the title of “Metastatic Hepatocellular Carcinoma -Pipeline Insight, 2017”. The study highlights the pharmacological action of various therapeutics and their history of research and development activities.
The study illustrates the distinctive pathological features of metastatic HCC, along with a brief review of pathological features, staging, treatment and prognosis. Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and occurs predominantly in patients with underlying chronic liver disease and cirrhosis. HCC commonly metastasises to lungs, lymph nodes, adrenal gland and bones, including the skull. The overall prognosis of patients with metastatic HCC is poor. The report further adds that the risk factors associated with hepatocellular carcinoma are Hepatitis B virus (HBV) infection and hepatitis C virus (HCV) infection, alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, and chronic liver injury. To overcome this, randomised clinical trials are needed, which evaluate new treatment strategies.
Treatment options for HCC are divided into surgical therapies and nonsurgical therapies, which may be liver-directed or systemic (chemotherapy, molecularly targeted therapy, hormone therapy). A comparative pipeline therapeutics valuation of Metastatic Hepatocellular Carcinoma by advance stage, therapy type, route of administration (RoA) and molecule type is also covered in the report.
Moreover, this study provides comprehensive information on the pipeline products with a comparative analysis of the products at various stages of development. The coverage of pipeline products based on the numerous stages of development going from early development to approved or issued stage. In this subsequent section, details of foremost pipeline products which includes, product description, licensing, collaboration details and other developmental activities are also mentioned. This study has been built using proprietary databases along with latest updates and featured news & press releases from various university sites and industry-specific third party sources.
For a competitive analysis, the research has listed key companies operating in the market, focusing on their research and development efforts, adoption to changing trends and their efforts to discover new therapeutics for metastatic hepatocellular carcinoma. Also, the report covers dormant and discontinued pipeline projects related to the metastatic hepatocellular carcinoma.
Request a Sample with TOC in a PDF format : http://www.marketresearchhub.com/enquiry.php?type=S&repid=1265407
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org